Answers are grounded in this paper and cite their sources.
BACKGROUND AND OBJECTIVES: A novel α-synuclein (syn) seed amplification assay (synSAA) differentiates 2 types of syn-seeds in CSF: type1, associated with Lewy bodies (LBs), and type2, associated with glial-cytoplasmic inclusions, the hallmark of multiple system atrophy (MSA). However, syn-copathology extends beyond synucleinopathies, and copathologies are increasingly relevant. Different syn-seeds have been assessed in highly characterized research cohorts, but data assessing type and frequency in patients from routine clinical encounters are lacking. Hence, our objective was to determine frequency, type, and clinical association of different syn-seeds in CSF in a large cohort from a movement disorders (MDs) clinic. METHODS: This cross-sectional study included consecutive patients from a MD clinic between 2009 and 2025. CSF was tested with synSAA and clinical data derived from medical records. RESULTS: We recruited 1,059 patients (mean age 70.5 ± 10.5 years; 38.4% female; mean disease duration 4.0 ± 4.6 years). Syn-seeds were detected in 54.2% of patients, with type1-seeds predominating (88.5%). High synSAA positivity was observed in Parkinson disease (PD) (84.7%), dementia with LB (93.4%), MSA (84.5%), isolated REM-sleep behavior disorder (iRBD) (80.0%), and normal pressure hydrocephalus (NPH) with PD (87.0%). Undetermined hypokinetic MD showed 53.7% positivity. Moderate proportions (∼25-33%) were detected in Alzheimer disease, progressive supranuclear palsy (PSP), corticobasal syndrome, and idiopathic NPH without PD, while other neurologic disorders showed 20.9% positivity. Type2-seeds were the major seed type in MSA (79.6% of syn-seeds) and minor type in PD (6.2%), PSP (9.1%), and undetermined hypokinetic MD (13.8%). Overall, type2-seeds were present in only 2.6% of non-MSA patients. Patients with type1-seeds had worse olfaction and more hallucinations. Multivariable regression identified impaired olfaction (OR = 0.67 per point increase of identified smells out of 12, higher scores indicating better olfaction) significantly associated with type1-seeds. DISCUSSION: Our results provide reference data on syn-seed frequency in routine clinical patients, demonstrating that type1-seeds indicate common underlying syn-pathology or copathology associated with hyposmia and hallucinations. Type2-seeds are specific to MSA and detection of type2-seeds outside the clinical MSA spectrum can improve diagnosis of patients with atypical presentations because our results match neuropathologic MSA studies. In vivo identification of different seed types will improve diagnosis, clinical trial stratification, and development of targeted therapies.
No takes yet. Share an insight, caveat, or question.
Weber et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: